A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Metastatic Cancer Clinical Trial

Official title:

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02697591
• Other study ID #: INCAGN 1876-101
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: June 20, 2016
• Est. completion date: December 16, 2019

Study information

• Verified date: February 2021
• Source: Incyte Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts. Part 1 is dose escalation and safety expansion which determines the optimal dose and maximum number of tolerated doses. Part 2 is dose expansion in which Part 1 recommended dose will be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 16, 2019
• Est. primary completion date: December 16, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.

• Part 1: Participants with advanced or metastatic solid tumors.

• Part 2: Participants with advanced or metastatic adenocarcinoma of endometrium, melanoma, non-small cell lung cancer, and renal cell carcinoma.

• Participants who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or participants who refuse standard treatment.

• Presence of measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.

Exclusion Criteria:

• Laboratory and medical history parameters not within the protocol-defined range.

• Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.

• Has not recovered to = Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy.

• Receipt of a live vaccine within 30 days of planned start of study therapy.

• Active autoimmune disease.

• Prior treatment with any tumor necrosis factor super family agonist.

• Known active central nervous system metastases and/or carcinomatous meningitis.

• Evidence of active, non-infectious pneumonitis or history of interstitial lung disease.

• Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.

Related Conditions & MeSH terms

• Advanced Malignancies
• Metastatic Cancer
• Neoplasm Metastasis

Intervention

Drug:
• INCAGN01876
Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	MSK Westchester	Harrison	New York
United States	The Angeles Clinic and Research Institute	Los Angeles	California
United States	Memorial Sloan Kettering at Monmouth	Middletown	New Jersey
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Yale University	New Haven	Connecticut
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Incyte Biosciences International Sàrl

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) and as Per the Severity	AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A treatment-emergent AE is any AE either reported for first time or worsening of a pre-existing event after the first dose of study drug. Grade 1 AEs is defined as Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 AEs is defined as Moderate; minimal, local, or non-invasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3 AEs is defined as the severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living and Grade 4 AEs as life-threatening consequences; urgent intervention indicated. Data is reported for Grade 3 and higher severity for this outcome measure.	From screening through 60 days after end of treatment, up to Month 15
Secondary	Maximum Observed Plasma Concentration (Cmax)		Day 1 of Cycles 1 and 6 post-dose
Secondary	Time to Maximum Concentration (Tmax)		Day 1 of Cycles 1 and 6 post-dose
Secondary	Minimum Observed Plasma Concentration Over the Dose Interval (Cmin)		Day 1 of Cycles 2, 3, 4, 6, and 7 post-dose
Secondary	Area Under the Plasma Time Curve From Time = 0 to the Last Measurable Concentration (AUC0-t)		Day 1 of Cycles 1 and 6 post-dose
Secondary	Objective Response Rate (ORR) Per RECIST v1.1 and Modified RECISTv1.1 (mRECIST)	ORR is defined as the percentage of participants having complete response (CR) or partial response (PR), as determined by investigator assessment of radiographic disease assessments. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm.	Baseline and every 8 weeks for the first 12 months and then every 12 weeks thereafter up to 15 months
Secondary	Duration of Response (DOR) Per RECIST and mRECIST	DOR is defined as the time from earliest date of disease response (CR or PR) until earliest date of disease progression, as determined by investigator assessment of radiographic disease assessments per RECIST v1.1 and mRECIST, or death due to any cause if occurring sooner than progression. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm.	Baseline and every 8 weeks for the first 12 months and then every 12 weeks thereafter up to 15 months
Secondary	Duration of Disease Control Per RECIST and mRECIST	Duration of disease control (CR, PR, and stable disease [SD]), as measured from first report of SD or better until disease progression, as determined by investigator assessment of radiographic disease assessments per RECIST v1.1 and mRECIST, or death due to any cause if occurring sooner than progression. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm. Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.	Baseline and every 8 weeks for the first 12 months and then every 12 weeks thereafter up to 15 months
Secondary	Progression Free Survival (PFS) Per RECIST and mRECIST	PFS is defined as the time from date of first dose of study drug until the earliest date of disease progression, as determined by investigator assessment of objective radiographic disease assessments per RECIST v1.1 and mRECIST, or death due to any cause if occurring sooner than progression. Progression is defined by RECIST and mRECIST as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study and an absolute lesion increase of at least 5 mm or the appearance of new lesions.	Baseline and every 8 weeks for the first 12 months and then every 12 weeks thereafter up to 15 months